469 results
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
broilers
I/C
DL-methionine, L-methionine, L-methionine
O
improved average daily gain (ADG), improved feed conversion ratio (FCR)
P
patients with mesial temporal lobe epilepsy (MTLE) and hippocampal sclerosis (HS)
I/C
semi-structured interviews, non-depression group (NDG) and depression group (DG), control group
O
volumetric patterns on magnetic resonance imaging, presence of left (L-) or right (R-) MTLE-HS, reduced eTIV in the DG compared to NDG and control group
P
hypertensive disorder, intrauterine growth restriction
I/C
l-arginine supplementation, no l-arginine supplementation
O
plasma nitric oxide concentrations, birth outcomes
P
GNB suspected for carbapenemase production
I/C
Xpert Carba-R assay, Other methods of detecting carbapenemase genes in GNB
O
Accuracy of Xpert Carba-R assay in detecting carbapenemase genes in GNB
P
patients with hypothyroidism
I/C
L-thyroxine (L-T4) administration before breakfast, L-T4 administration at bedtime
O
hormone thyrotropin (TSH), free triiodothyronine (FT3), FT4 level
P
PD patients
I/C
Pramipexole (P) or levodopa (L) treatment, P+L combination therapy, L monotherapy
O
clinical efficacy, UPDRS scores, Hamilton depression rating scale score, adverse events
P
Evolut R/Pro, Sapien 3
I/C
transcatheter aortic valve implantation (TAVI), Evolut R/Pro vs Sapien 3
O
all-cause mortality (short and long-term), stroke, bleeding, permanent pacemaker implantation (PPI), acute kidney injury (AKI), major vascular complication, device success, moderate-severe aortic regurgitation (AR), pressure gradients
P
muscle-invasive bladder carcinoma
I/C
neoadjuvant PD-(L)1 inhibitors, PD-(L)1 inhibitors alone, PD-(L)1 inhibitors plus other ICI, PD-(L)1 inhibitors plus chemotherapy
O
pCR, pPR, Grade≥ 3 irAEs rate, OS, RFS
P
patients with pretreated advanced esophagogastric cancer
I/C
PD-(L)1 antibody, chemotherapy, supportive treatment, supportive treatment, PD-(L)1 antibody, chemotherapy
O
overall survival (OS), progression-free survival (PFS), all grades and serious treatment-related adverse events (TRAEs)